Sanara Medtech Inc. (SMTI) - Q2 2024 10-Q Summary
Business Context and Reporting Period
Company: Sanara Medtech Inc.
Reporting Period: Quarter ended June 30, 2024 (Q2 2024)
Business Overview: A medical technology company focused on surgical, chronic wound, and skincare markets. The company recently reorganized its reporting into two segments: Sanara Surgical (soft tissue repair and bone fusion products) and Tissue Health Plus (THP) (value-based wound care services). THP has not yet commercially launched and currently reports no revenue.
Key Financial Metrics (Six Months Ended June 30, 2024)
| Metric | 2024 (6 Months) | 2023 (6 Months) |
|---|---|---|
| Net Revenue | $38.70 million | $31.28 million |
| Gross Profit | $34.80 million | $26.96 million |
| Gross Margin | 90.0% | 86.2% |
| Net Loss | $(5.33) million | $(3.08) million |
| Net Loss Per Share (Basic/Diluted) | $(0.62) | $(0.37) |
| Operating Cash Flow | $(3.01) million (Used) | $(3.46) million (Used) |
| Cash and Equivalents (End of Period) | $6.15 million | $6.06 million |
| Total Debt (Long-term) | $14.37 million | $9.11 million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 24% year-over-year (YoY) to $38.7 million, driven primarily by increased sales of soft tissue repair products (CellerateRX Surgical) due to market penetration and distribution expansion.
- Margin Expansion: Gross margin improved to 90% from 86% YoY. This was largely due to the elimination of royalties on CellerateRX Surgical following the August 2023 Applied Asset Purchase.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose to $35.1 million (from $26.8 million) due to higher sales commissions ($3.8 million increase), executive separation costs ($0.9 million), and acquisition costs ($0.4 million).
- Debt Restructuring: The company entered a new $55.0 million CRG Term Loan facility in April 2024, borrowing $15.0 million to repay the prior Cadence Term Loan. This increased interest expense significantly compared to the prior year.
- Segment Reporting: The company now reports two segments. Sanara Surgical generated all revenue, while THP incurred operating losses of $2.64 million for the six-month period as it prepares for a commercial launch in late 2025.
Guidance, Outlook, and Risks
- Outlook: Management expects THP operating expenses and net loss to increase by approximately $4.0 to $5.0 million in the second half of 2024 due to investments in the technology platform. The THP program is targeted for commercial launch in the second half of 2025.
- Debt Covenants: The new CRG Term Loan requires the company to maintain minimum annual revenue targets: $60.0 million for 2024, $75.0 million for 2025, increasing to $105.0 million by 2028. It also requires maintaining liquidity of at least $3.0 million.
- Liquidity: The company believes current cash, operating cash flows, and available proceeds from the CRG Term Loan ($39.8 million remaining capacity) are sufficient to fund operations for at least the next 12 months. Another borrowing under the CRG facility is expected in H2 2024.
- Risks: Key risks include the ability to meet revenue covenants, the success of the THP value-based care model, dependence on licensed technologies, and the impact of high interest rates on the new debt facility.
Investor Verification Checklist
- Revenue Covenants: Verify if the company is on track to meet the $60.0 million annual revenue minimum required by the CRG Term Loan for 2024.
- THP Burn Rate: Monitor the actual cash burn of the THP segment against the projected $4.0–$5.0 million increase in expenses for H2 2024.
- Debt Service: Review the impact of the 13.25% interest rate (including 5.25% paid-in-kind) on future cash flows and principal balance growth.
- Related Party Transactions: Review ongoing royalty and service agreements with related parties (e.g., Catalyst, Rochal) to ensure terms remain favorable.
- Product Pipeline: Assess progress on the Precision Healing diagnostic imager and LFA, which are critical to the THP value proposition.